Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-03-15
2005-03-15
Tate, Christopher R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S004300, C514S252140, C514S253030, C514S323000, C514S330000, C514S018700, C514S415000, C540S229000
Reexamination Certificate
active
06867184
ABSTRACT:
The present invention provides methods of treating diabetic cardiomyopathy, the methods comprising administering to a patient having or at risk of having diabetic cardiomyopathy a therapeutically effective amount of a glycogen phosphorylase inhibitor. The present invention also provides methods of treating diabetic cardiomyopathy, the methods comprising administering to a patient having 1) diabetes and 2) having cardiovascular disease, ischemic heart disease, congestive heart failure, congestive heart failure but not having coronary arteriosclerosis, hypertension, diastolic blood pressure abnormalities, microvascular diabetic complications, abnormal left ventricular function, myocardial fibrosis, abnormal cardiac function, pulmonary congestion, small vessel disease, small vessel disease without atherosclerotic cardiovascular disease or luminal narrowing, coagulopathy, cardiac contusion, or having had or at risk of having a myocardial infarction a therapeutically effective amount of a glycogen phosphorylase inhibitor.
REFERENCES:
patent: 4786641 (1988-11-01), Goldmann et al.
patent: 5990111 (1999-11-01), Johnson
patent: 5998463 (1999-12-01), Hulin et al.
patent: 6277877 (2001-08-01), Hoover et al.
patent: 6294538 (2001-09-01), Mylari
patent: 0846464 (1997-12-01), None
patent: 0884050 (1998-12-01), None
patent: 0 978 279 (2000-02-01), None
patent: 1 088 824 (2001-04-01), None
patent: WO9524391 (1995-09-01), None
patent: WO9639384 (1996-12-01), None
patent: WO9639385 (1996-12-01), None
patent: WO9709040 (1997-03-01), None
patent: WO9731901 (1997-09-01), None
patent: WO0880964 (1998-05-01), None
patent: WO9840353 (1998-09-01), None
patent: WO9850359 (1998-11-01), None
patent: WO9926659 (1999-06-01), None
patent: WO 0168055 (2001-09-01), None
patent: WO 0168092 (2001-09-01), None
patent: WO 0220530 (2002-03-01), None
Bell, David S. H.,Diabetic Cardiomyopathy: A unique entity or a complication of coronary artery disease?, Diabetes Care, vol. 18, No. 5, 708-714, May 1995.
Fein, Frederick S., et al.,Diabetic Cardiomyopathy, Cardiovascular Drugs and Therapy, 1994; 8:65-73.
Hoover, Dennis J., et al.,Indole-2-carboxamide Inhibitors of Human Liver Glycogen Phosphorylase, American Chemical Society, 1998, 41, 2934-2938.
Martin, et al., “Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo”,Proc. Natl. Acad. Sci., 95:1776-1781 (1998).
European Search Report, Application No. 01 300 575.6-2123, dated Dec. 19, 2003.
Benson Gregg C.
Chism B. Dell
Cohen Mark J.
Crissey Todd M.
Pfizer Inc.
LandOfFree
Methods of treating diabetic cardiomyopathy using glycogen... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating diabetic cardiomyopathy using glycogen..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating diabetic cardiomyopathy using glycogen... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3458402